• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rallybio Corporation (Amendment)

    1/2/24 4:29:51 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    SC 13G/A 1 d683049dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Rallybio Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    75120L100

    (CUSIP Number)

    December 27, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 75120L100

     

      1.    

      Name of Reporting Person:

     

      Novo Holdings A/S

      2.  

      Check the Appropriate Box if a Member of Group (See Instructions):

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only:

     

      4.  

      Citizenship or Place of Organization:

     

      Denmark

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power:

     

      1,767,861

       6.   

      Shared Voting Power:

     

      0

       7.   

      Sole Dispositive Power:

     

      1,767,861

       8.   

      Shared Dispositive Power:

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      1,767,861

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

     

      ☐

    11.  

      Percent of Class Represented By Amount In Row (9):

     

      4.7% (1)

    12.  

      Type of Reporting Person:

     

      CO

     

    (1)

    Based upon 37,793,705 shares of the Issuer’s Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2023.

     

    2


    This Amendment No. 1 amends the Schedule 13G originally filed with the SEC on November 17, 2022 (the “Schedule”) to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Stock.

     

    Item 1.    (a)    Name of Issuer:
         

    Rallybio Corporation

       (b)    Address of Issuer’s Principal Executive Offices:
         

    234 Church Street, Suite 1020

         

    New Haven, CT, 06510

    Item 2.    (a)    Name of Person Filing:
         

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

       (b)    Address or Principal Business Office or, if none, Residence:
         

    Tuborg Havnevej 19

    2900 Hellerup, Denmark

       (c)    Citizenship or Place of Organization:
         

    Denmark

       (d)    Title of Class of Securities:
         

    Common Stock

       (e)    CUSIP Number:
         

    75120L100

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      

    Not applicable.

     

    3


    Item 4.

    Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

      

    Amount beneficially owned:

         1,767,861        (1 ) 

    (b)

      

    Percent of class:

         4.7 %       (2 ) 

    (c)

      

    Number of shares as to which such person has:

         
      

    (i) Sole power to vote or to direct the vote:

         1,767,861        (1 ) 
      

    (ii) Shared power to vote or to direct the vote:

         0   
      

    (iii) Sole power to dispose or to direct the disposition of:

         1,767,861        (1 ) 
      

    (iv) Shared power to dispose or to direct the disposition of:

         0     

     

    (1)

    Novo Holdings A/S has the sole power to vote and dispose of the shares, and no individual or other entity is deemed to hold any beneficial ownership in the shares.

    (2)

    Based upon 37,793,705 shares of the Issuer’s Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s 10-Q filed with the SEC on November 9, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10.

    Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 2, 2024    

    Novo Holdings A/S

     

    /s/ Barbara Fiorini Due

    By: Barbara Fiorini Due

    Its: General Counsel, Finance & Operations

    Get the next $RLYB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by JP Morgan

    JP Morgan downgraded Rallybio from Overweight to Neutral

    5/15/24 7:39:44 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by Jefferies with a new price target

    Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

    2/7/24 6:42:56 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    SEC Filings

    View All

    SEC Form 10-Q filed by Rallybio Corporation

    10-Q - Rallybio Corp (0001739410) (Filer)

    8/7/25 8:33:38 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rallybio Corp (0001739410) (Filer)

    8/7/25 8:08:49 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - Rallybio Corp (0001739410) (Filer)

    7/8/25 8:08:55 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Boudreau Helen M

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:10:09 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chung Wendy

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:09:20 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunt Ronald

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:08:25 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

    – Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an Upfront Equity Payment of $7.5 Million – – Cash Runway into Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments. "The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116,

    8/7/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

    – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment of $7.5 million and near term milestones. With the upf

    7/8/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    View All

    Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

    -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

    6/29/23 7:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

    -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

    3/6/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

    1/31/23 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    11/12/24 10:34:15 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rallybio Corporation

    SC 13G - Rallybio Corp (0001739410) (Subject)

    7/30/24 9:06:36 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    7/30/24 12:47:55 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Financials

    Live finance-specific insights

    View All

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

    -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

    12/20/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care